Form 4: enGene Holdings Director Philip Astley-Sparke Granted Stock Options

enGene Holdings Inc. Director Philip Astley-Sparke was granted 45,000 stock options with an exercise price of $3.83, vesting over three years.

Summary

• Philip Astley-Sparke, a Director of enGene Holdings Inc. (ENGN), was granted 45,000 stock options.
• The transaction date for the option grant was July 8, 2025.
• The exercise price for these stock options is $3.83 per share.
• The options vest at a rate of one-third on each of the first, second, and third anniversaries of Mr. Astley-Sparke's appointment date to the Board, which was July 8, 2025.
• The stock options have an expiration date of July 8, 2035.
• Following this transaction, Philip Astley-Sparke beneficially owns 45,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine compensation event that aligns the director's interests with long-term shareholder value creation, indicating commitment. This is generally viewed as a neutral to slightly positive development.

Positives

• The grant of stock options to a director aligns their long-term interests with those of the shareholders, incentivizing value creation.
• The 10-year expiration period for the options provides a substantial window for the director to realize value, encouraging sustained commitment.

Risks

• The value of the granted stock options is directly tied to the future performance of enGene Holdings Inc.'s stock price; if the stock price does not exceed the $3.83 exercise price, the options may expire worthless.
• The vesting schedule requires Mr. Astley-Sparke to remain on the Board for three years to fully realize the benefit of the entire option grant.

Future Outlook

The vesting schedule of the stock options over three years implies a commitment from the director and is designed to incentivize long-term performance and continued service to the company.

Industry Context

The grant of stock options to directors is a common and standard practice in the biotechnology and pharmaceutical industries, where enGene Holdings Inc. likely operates. This compensation method is widely used to attract and retain experienced talent, aligning the interests of management and board members with the long-term value creation for shareholders.

Comparison to Industry Standards

• The grant of stock options to directors is a standard practice in the biotechnology and pharmaceutical industries to align long-term incentives with shareholder value creation.
• The specific size of the grant (45,000 options) and the exercise price ($3.83) would typically be evaluated against compensation benchmarks for directors at companies of similar market capitalization, stage of development, and industry sector, though specific comparable data is not provided in this filing.

Management Changes

Related Party Transactions

• Grant of 45,000 stock options to Philip Astley-Sparke, a Director of enGene Holdings Inc., with an exercise price of $3.83 per share. This is considered a related party transaction as directors are related parties.

Stakeholder Impact

• Shareholders: The grant of stock options to a director is intended to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through increased focus on value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.
• Customers: No direct impact on customers is indicated by this specific filing.
• Suppliers: No direct impact on suppliers is indicated by this specific filing.
• Creditors: No direct impact on creditors is indicated by this specific filing.

Next Steps

• Vesting of 1/3 of the options on July 8, 2026.
• Vesting of 1/3 of the options on July 8, 2027.
• Vesting of 1/3 of the options on July 8, 2028.
• Potential exercise of the vested options by Philip Astley-Sparke at any time before their expiration on July 8, 2035.

Key Dates

Keywords

enGene Holdings Inc., ENGN, Stock Option, Director, Insider Transaction, SEC Form 4, Equity Grant, Executive Compensation, Beneficial Ownership